Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · AJANTPHARM

AJANTA PHARM

HealthcarePharmaceuticals & Biotechnology₹40878 cr market cap
₹3268.90 ▼ -0.15% today As of 19 Nov 2026
52-week low ₹2458.1052-week high ₹3718.20

-12.0% from the 52-week high · +33.2% above the low

Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 7,713 full-time employees. The company went IPO on 2000-06-05. The firm provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The firm is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. The company has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The firm's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.

The short version. AJANTA PHARM reported revenue of ₹1,794 crore for Sep 2026, up 32.5% from a year earlier. Net profit was ₹388 crore (up 49.2% year on year). Return on equity was 23.3% in Mar 2026. Promoter holding was 63.47% in Sep 2026, down 2.79 points over 8 quarters.

1 · The price

How has the stock traded?

AJANTA PHARM trades 12.0% below its 52-week high and 33.2% above its 52-week low.

Change over period: —

1M-0.8%
3M-11.5%
6M+2.7%
1Y+33.2%

2 · The business

Is it growing?

Sales, year on year+32.5%

Sep 2026 revenue of ₹1,794 cr.

Profit, year on year+49.2%

Sep 2026 net profit of ₹388 cr.

Net margin21.6%

2.4 pts higher than a year earlier.

3-year growth21.6% profit

Revenue compounded at 13.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue17941626142213751354130311701146
Net profit388334267274260255225233
Net margin %21.620.618.819.919.219.619.220.3
EPS (₹)31.0626.7521.3521.9120.8320.4418.0318.64

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue54534648420937433341289025882055
Net profit1056920816588713654468387
Net margin %19.419.819.415.721.322.618.118.8
EPS (₹)84.5273.6864.8245.8955.6250.3835.7329.57

3 · The quality

How well does it turn capital into profit?

Return on equity was 23.3% in Mar 2026; debt to equity is 0.05.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %23.324.322.917.3
Return on capital %29.430.129.921.2
EBITDA margin %27.928.529.323.0
Net margin %18.819.419.015.3

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR13.6%14.0%
Profit CAGR21.6%10.1%
Debt to equity0.05
Interest cover86.5x
Current ratio2.64
P/E ratio32.5

4 · The owners

Who holds it, and are they adding?

Promoter holding63.47%

Down 2.79 pts over 8 quarters.

Foreign institutions7.63%

Down 1.63 pts over 8 quarters.

Domestic institutions21.94%

Up 4.92 pts over 8 quarters.

Mutual fund schemes208

+52 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter66.2666.2666.2666.2566.2566.2563.4863.47-2.79
FII9.268.868.868.537.988.267.687.63-1.63
DII17.0217.4817.517.918.5818.3721.821.94+4.92
Public7.457.397.387.327.197.127.036.96-0.49

Mutual fund holdings · Oct 2026

208 schemes hold this stock

156 the month before.

  • LIC MF CHILDREN’S FUND5.19% of NAV
  • PGIM INDIA HEALTHCARE FUND5.16% of NAV
  • UTI - Healthcare Fund4.29% of NAV
  • SAMCO FLEXICAP FUND4.28% of NAV
  • ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND4.17% of NAV
  • NIPPON INDIA PHARMA FUND3.53% of NAV
  • UTI Focused Fund (30 stocks)3.02% of NAV
  • SAMCO ELSS TAX SAVER FUND2.89% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for AJANTA PHARM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about AJANTA PHARM

What is the AJANTA PHARM share price?

AJANTA PHARM (AJANTPHARM) last closed at ₹3,268.90, down 0.15% on the day. Its 52-week range is ₹2,458.10 to ₹3,718.20.

What is the market cap of AJANTA PHARM?

AJANTA PHARM has a market capitalisation of about ₹40,878 crore. Its price-to-earnings ratio is 32.5.

How are AJANTA PHARM's latest results?

AJANTA PHARM reported revenue of ₹1,794 crore for Sep 2026, up 32.5% from a year earlier. Net profit was ₹388 crore (up 49.2% year on year). Return on equity was 23.3% in Mar 2026. Promoter holding was 63.47% in Sep 2026, down 2.79 points over 8 quarters.

Who owns AJANTA PHARM?

As of Sep 2026, shareholding was: Promoter 63.47%, FII 7.63%, DII 21.94%, Public 6.96%.

How many mutual funds hold AJANTA PHARM?

208 mutual fund schemes held AJANTA PHARM in October 2026. That compares with 156 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 10 Nov 2025 · Interim Dividend - Rs. 28
  • 06 Nov 2024 · Interim Dividend - Rs. 28
  • 08 Feb 2024 · Interim Dividend - Rs. 26
  • 04 Aug 2023 · Special Dividend - Rs. 15
  • 04 Aug 2023 · Interim Dividend - Rs. 10
  • 11 Nov 2022 · Interim Dividend - Rs. 7

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.